Effect of Budesonide on transform growth factor-β1 induced vascular endothelial growth factor release by lung fibroblasts

Abstract:

Objective：To observe the effect of glucocorticoid（Budesonide） on TGF-β1 induced human fetal lung fibroblasts-1（HFL-1） secretion and vascular endothelial growth factor（VEGF） pro－duction and to discuss its mechanism. Methods：HFL-1 were cultured in vitro and were treated with various concentrations of Budesonide in the presence of TGF-β1 stimulation. Post-culture media were collected and VEGF content was tested by enzyme-linked immunosorbent（ELISA）. The cell lysates were subjected to Western blot analysis to test the protein expressions of phosphor-ERK MAPK and phosphor-Smad3. Results：Budesonide can induce VEGF release by HFL-1 in a dose-dependent manner（P<0.05）. Budesonide with high concentration can suppress the TGF-β1 induced VEGF release（P<0.05）. The protein expressions of phosphor-ERK MAPK and phosphor-Smad3 were decreased after Budesonide pre-treatment（P<0.05）. Conclusions：Budesonide may reduce TGF-β1 induced VEGF production in the lung，probably through the Smad/ERK signaling pathway，which may provide new sight into the molecular mechanism underlying glucocorticoids therapy for airway inflammatory diseases.